{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:38:51Z","timestamp":1784572731210,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12955-017-0794-6","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T10:01:03Z","timestamp":1513936863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1421-9137","authenticated-orcid":false,"given":"Michelle","family":"Lui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gallo-Hershberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"794_CR1","doi-asserted-by":"crossref","unstructured":"Benson III, AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr. et al. recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918\u20132926.","DOI":"10.1200\/JCO.2004.04.132"},{"key":"794_CR2","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JCH, Yamamoto B, O\u2019Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327\u201334.","journal-title":"J Clin Oncol"},{"key":"794_CR3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"794_CR4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Palmero R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol"},{"key":"794_CR5","doi-asserted-by":"crossref","unstructured":"O\u2019Brien BE, Kaklamani VG and Benson III AB. (2005) The assessment and treatment of cancer treatment-related diarrhea. Clin Colorectal Cancer. 2005;4:375\u2013381.","DOI":"10.3816\/CCC.2005.n.009"},{"key":"794_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.soncn.2003.09.007","volume":"19","author":"CS Viele","year":"2003","unstructured":"Viele CS. Overview of chemotherapy-induced diarrhea. Semin Oncol Nurs. 2003;19:2\u20135.","journal-title":"Semin Oncol Nurs"},{"key":"794_CR7","first-page":"1984","volume-title":"Devita, Hellman, and Rosenberg's cancer: principles & practice of oncology","author":"NI Cherny","year":"2015","unstructured":"Cherny NI, Werman B. Diarrhea and constipation. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Devita, Hellman, and Rosenberg's cancer: principles & practice of oncology. Philadelphia: Wolters Kluwer Health; 2015. p. 1984\u201391."},{"issue":"2","key":"794_CR8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0885-3924(99)00149-9","volume":"19","author":"S Kornblau","year":"2000","unstructured":"Kornblau S, Benson IIIAB, Catalano R, et al. Management of cancer treatment-related diarrhea: issues and therapeutic strategies. Journal of pain and symptomatic management. 2000;19(2):118\u201329.","journal-title":"Journal of pain and symptomatic management"},{"key":"794_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3747\/co.2007.96","volume":"14","author":"JA Maroun","year":"2007","unstructured":"Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian working group on chemotherapy-induced diarrhea. Curr Oncol. 2007;14:13\u201320.","journal-title":"Curr Oncol"},{"key":"794_CR10","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/cncr.20594","volume":"101","author":"T Delaunoit","year":"2004","unstructured":"Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, et al. Mortality associated with daily bolus 5-fluorouracil\/leucovorin administered in combination with either irinotecan or oxaliplatin: results from intergroup trial N9741. Cancer. 2004;101:2170\u20136.","journal-title":"Cancer"},{"key":"794_CR11","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. National Institutes of Health, National Cancer Institute. 2010. \nhttps:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf\n\n. Accessed 15 Jan 2017."},{"key":"794_CR12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11136-011-0031-4","volume":"21","author":"TM Atkinson","year":"2012","unstructured":"Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012;21:1159\u201364.","journal-title":"Qual Life Res"},{"key":"794_CR13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/annonc\/mdp287","volume":"20","author":"M Cirillo","year":"2009","unstructured":"Cirillo M, Venturini M, Circcarelli L, Coati F, Bortolami O, Verlato G. Clinician versus nurse symptom reporting using the National Cancer Institute \u2013 common terminology criteria for adverse events during chemotherapy: results of a comparison based on patient\u2019s self-reported questionnaire. Ann Oncol. 2009;20:1929\u201335.","journal-title":"Ann Oncol"},{"key":"794_CR14","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","volume":"7","author":"E Basch","year":"2006","unstructured":"Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Scher H, et al. Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse effects: results of a questionnaire-based study. Lancet Oncol. 2006;7:903\u20139.","journal-title":"Lancet Oncol"},{"key":"794_CR15","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","volume":"22","author":"EK Fromme","year":"2004","unstructured":"Fromme EK, Eilers KM, Mori M, Hsieh Y, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol. 2004;22:3485\u201390.","journal-title":"J Clin Oncol"},{"key":"794_CR16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E. Perspective: the missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865\u20139.","journal-title":"N Engl J Med"},{"key":"794_CR17","unstructured":"US Food and Drug Administration Guidance for Industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, MD: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2009."},{"key":"794_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1525822X02239569","volume":"15","author":"GW Ryan","year":"2003","unstructured":"Ryan GW, Bernard HR. Techniques to identify themes. Field Methods. 2003;15:85\u2013109.","journal-title":"Field Methods"},{"key":"794_CR19","first-page":"43","volume":"19","author":"IIJE Barlett","year":"2001","unstructured":"Barlett IIJE, Kotrlik JW, Higgins CC. Organizational research: determining appropriate sample size in survey research. Inf Technol Learn Perform J. 2001;19:43\u201350.","journal-title":"Inf Technol Learn Perform J"},{"key":"794_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.21500\/20112084.854","volume":"3","author":"M Matsunaga","year":"2010","unstructured":"Matsunaga M. How to factor-analyze your data right: Do\u2019s, Don\u2019ts, and how-To\u2019s. International Journal of Psychological Research. 2010;3:97\u2013110.","journal-title":"International Journal of Psychological Research"},{"key":"794_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/0013164405282485","volume":"66","author":"RK Henson","year":"2006","unstructured":"Henson RK, Roberts JK. Use of exploratory factor analysis in published research: common errors and some comment on improved practice. Educ Psychol Meas. 2006;66:393\u2013416.","journal-title":"Educ Psychol Meas"},{"key":"794_CR22","volume-title":"STOP-IT: an intervention for chronic diarrhea in people with HIV","author":"MK Klebert","year":"2008","unstructured":"Klebert MK. STOP-IT: an intervention for chronic diarrhea in people with HIV. Louis: Dissertation. University of Missouri- St; 2008."},{"key":"794_CR23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1477-7525-11-208","volume":"11","author":"DA Andrae","year":"2013","unstructured":"Andrae DA, Patrick DL, Drossman DA, Covington PS. Evaluation of the irritable bowel syndrome quality of life (IBS-QOL) questionnaire in diarrhea-predominant irritable bowel syndrome patients. Health Qual Life Outcomes. 2013;11:208.","journal-title":"Health Qual Life Outcomes"},{"key":"794_CR24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-230X-8-30","volume":"8","author":"AK Roalfe","year":"2008","unstructured":"Roalfe AK, Roberts LM, Wilson S. Evaluation of the Birmingham IBS symptom questionnaire. BMC Gastroenterol. 2008;8:30.","journal-title":"BMC Gastroenterol"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-017-0794-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T10:02:13Z","timestamp":1513936933000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-017-0794-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1186\/s12955-017-0794-6","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"249"}}